The high level of efficacy and safety demonstrated by Sputnik V speaks of a significant victory won by Russia in the global vaccine race. The American edition of The Wall Street Journal writes about it.
Rambler wrote that earlier the interim results of the third phase of clinical trials of the Russian vaccine against coronavirus Sputnik V were published in the leading medical journal The Lancet. In a study based on an analysis of data from nearly 20,000 trial participants, three quarters of whom received the vaccine and one quarter received a placebo, it was noted that the effectiveness of vaccination against COVID-19 was 91.6%.
The American edition emphasized that the effectiveness of the Russian drug is almost equal to the vaccines developed by the American Moderna Inc., Pfizer Inc. and the German BioNTech SE. At the same time, the Russian vaccine is significantly superior to the drug from the British-Swedish pharmaceutical company AstraZeneca PLC.
The Lancet has published the results of the tests “Sputnik” V
Sputnik V's strong performance represents “a significant victory for Russian President Vladimir Putin in the global vaccination race, providing a vote of confidence in the capabilities of Russian science and medicine,” the article says.
American journalists also noted that the test results prove the irrelevance of the criticism that Moscow faced after quickly creating a vaccine.
Sputnik V is the world's first vaccine against COVID-19. It was developed by the Gamaleya Research Center for Epidemiology and Microbiology and the 27th Central Research Institute of the Russian Ministry of Defense.
Kostroma police officer fined relatives to fulfill the plan
Europe agreed to use Sputnik V on a transparent basis
Russia has resumed railway communication with Belarus
